AnaptysBio’s (ANAB) Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
- AnaptysBio price target raised to $42 from $36 at JPMorgan
- Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
- AnaptysBio price target raised to $52 from $36 at Guggenheim
- AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating